Aripiprazole psychiatric

Uzun, S., Kozumplik, O., Mimica, N. Folnegovic-Smalc, V. (2005). Aripiprazole An overview of a novel antipsychotic. Psychiatr. Danub, 17, 67-75. 

Centorrino F, Fogarty KV, Cimbolli P, Salvatore P, Thompson TA, Sani G, Cincotta SL, Baldessarini RJ. Aripiprazole initial clinical experience with 142 hospitalized psychiatric patients. J Psychiatr Pract 2005 ll(4) 241-7. 

Gupta, S. and P. Masand (2004). Aripiprazole review of its pharmacology and therapeutic use in psychiatric disorders. Ann Clin Psychiatry 16(3) 155-66. 

Observational studies In a hospital-based postmarketing surveillance study 80% of 799 patients with schizophrenia from 122 psychiatric hospitals were treated for 4 weeks with aripiprazole 10-30 mg/day (mean modal dose 15 mg/day) [57 ]. There were significant improvements in clinical current scales and the most frequent adverse reactions were insomnia, irritability, restlessness, nausea, and vomiting. 

Psychiatric The incidence of suicide-related events in patients with schizophrenia or bipolar disorder taking aripiprazole has been studied using administrative data from three US sources [65 "]. Suicide attempts and death by suicide were assessed in patients aged at least 18 years. Among 20489 antipsychotic drug users (8985 patient-years), unadjusted suicide event rates per 1000 patient-years were 21 for aripiprazole 24 for olanzapine 32 for quetiapine 20 for risperidone and 49 for ziprasidone. Compared with current users of the other antipsychotic... 

---